Muta Hospital, Fukuoka, Japan.
Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Endocr J. 2019 Jul 28;66(7):637-645. doi: 10.1507/endocrj.EJ18-0505. Epub 2019 May 9.
Low endogenous testosterone and sex hormone-binding globulin (SHBG) concentrations have been reported to be associated with metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD). However, little is known about the relationships between testosterone or SHBG and liver fibrosis in NAFLD. Thus, we aimed to clarify the relationships between serum testosterone or SHBG concentration and fibrosis-4 (FIB-4) index, a marker of liver fibrosis. Serum testosterone was assayed in various forms (total testosterone [TT], calculated free testosterone [cFT], calculated bioavailable testosterone [cbT], and SHBG) and metabolic markers were also measured in 363 Japanese men (mean age 51.1 ± 8.7 years) at routine health examinations. We then attempted to identify the factors contributing to liver fibrosis by investigating the associations between the metabolic markers, including testosterone, and FIB-4 index. People with a relatively high FIB-4 index (≥1.3) demonstrated lower cFT, cbT, homeostasis model assessment (HOMA)-β, low-density lipoprotein-cholesterol, and blood urea nitrogen, but higher SHBG, than those with a lower FIB-4 index (<1.3). There were no significant differences in HbA1c, fasting glucose concentration, HOMA-R, or metabolic syndrome prevalence between the two groups. Binary regression analysis revealed that SHBG ≥52 nmol/L and cFT <8.0 ng/dL were statistically significant risk factors for FIB-4 index ≥1.3. Receiver operating characteristic analysis revealed that cFT <7.62 ng/dL (area under the curve [AUC] = 0.639) and SHBG ≥49.8 nmol/L (AUC = 0.649) were the strongest risk factors for FIB-4 index ≥1.3. In contrast to previous findings showing low SHBG concentrations in NAFLD, we provide evidence that high SHBG and low bioactive testosterone are associated with liver fibrosis.
内源性睾酮和性激素结合球蛋白 (SHBG) 浓度降低与代谢综合征 (MetS) 和非酒精性脂肪性肝病 (NAFLD) 有关。然而,人们对睾酮或 SHBG 与 NAFLD 中肝纤维化之间的关系知之甚少。因此,我们旨在阐明血清睾酮或 SHBG 浓度与纤维化 4 指数(一种肝纤维化标志物)之间的关系。在常规健康检查中,我们对 363 名日本男性(平均年龄 51.1 ± 8.7 岁)的各种形式的血清睾酮(总睾酮 [TT]、计算游离睾酮 [cFT]、计算生物可利用睾酮 [cbT] 和 SHBG)进行了检测,并测量了代谢标志物。然后,我们通过研究代谢标志物(包括睾酮)与 FIB-4 指数之间的关联,试图确定导致肝纤维化的因素。FIB-4 指数较高(≥1.3)的人群的 cFT、cbT、稳态模型评估(HOMA)-β、低密度脂蛋白胆固醇和血尿素氮较低,但 SHBG 较高,而 FIB-4 指数较低(<1.3)的人群则相反。两组之间在 HbA1c、空腹血糖浓度、HOMA-R 或代谢综合征患病率方面无显著差异。二元回归分析显示,SHBG ≥52 nmol/L 和 cFT <8.0 ng/dL 是 FIB-4 指数≥1.3 的统计学显著危险因素。受试者工作特征分析显示,cFT <7.62 ng/dL(曲线下面积 [AUC] = 0.639)和 SHBG ≥49.8 nmol/L(AUC = 0.649)是 FIB-4 指数≥1.3 的最强危险因素。与之前在 NAFLD 中发现的低 SHBG 浓度相反,我们提供的证据表明,高 SHBG 和低生物活性睾酮与肝纤维化有关。